Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature

Rajul Kothari; Peter A Argenta; Jeffrey Fowler; Jori Carter; William Shimp

doi:10.2298/AOO1002032K

Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature

Rajul Kothari, Peter A Argenta, Jeffrey Fowler, Jori Carter, William Shimp

Obstetrics, Gynecology and Women's Health - Oncology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.

Original language	English (US)
Pages (from-to)	32-35
Number of pages	4
Journal	Archive of Oncology
Volume	18
Issue number	1-2
DOIs	https://doi.org/10.2298/AOO1002032K
State	Published - Jul 2010

Keywords

Antineoplastic Agents
Aromatase
Hormonal
Ovarian Neoplasms
Selective Estrogen Receptor Modulators
Tamoxifen

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.2298/AOO1002032K

OpenUrl availability

Full text

Cite this

@article{8bd067f2920a495889f0dd38206e9e6a,

title = "Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature",

abstract = "Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.",

keywords = "Antineoplastic Agents, Aromatase, Hormonal, Ovarian Neoplasms, Selective Estrogen Receptor Modulators, Tamoxifen",

author = "Rajul Kothari and Argenta, {Peter A} and Jeffrey Fowler and Jori Carter and William Shimp",

year = "2010",

month = jul,

doi = "10.2298/AOO1002032K",

language = "English (US)",

volume = "18",

pages = "32--35",

journal = "Archive of Oncology",

issn = "0354-7310",

publisher = "Institute of Oncology Sremska Kamenica",

number = "1-2",

}

TY - JOUR

T1 - Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease

T2 - A case report and review of the literature

AU - Kothari, Rajul

AU - Argenta, Peter A

AU - Fowler, Jeffrey

AU - Carter, Jori

AU - Shimp, William

PY - 2010/7

Y1 - 2010/7

N2 - Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.

AB - Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.

KW - Antineoplastic Agents

KW - Aromatase

KW - Hormonal

KW - Ovarian Neoplasms

KW - Selective Estrogen Receptor Modulators

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=78649496224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649496224&partnerID=8YFLogxK

U2 - 10.2298/AOO1002032K

DO - 10.2298/AOO1002032K

M3 - Article

AN - SCOPUS:78649496224

SN - 0354-7310

VL - 18

SP - 32

EP - 35

JO - Archive of Oncology

JF - Archive of Oncology

IS - 1-2

ER -

Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this